Meeting
2019 ASCO Annual Meeting
Efficacy and safety of pembrolizumab in patients with PD-L1 positive advanced biliary tract cancer (BTC): A prospective cohort study.
Authors
Junho Kang
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Junho Kang , Changhoon Yoo , Jae Ho Jeong , Boyeong Kang , YunJin Hong , Kyu-Pyo Kim , Baek-Yeol Ryoo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4082)
DOI
10.1200/JCO.2019.37.15_suppl.4082
Abstract #
4082
Poster Bd #
187
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2014 ASCO Annual Meeting
A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma.
First Author: David F. McDermott
Poster
2014 ASCO Annual Meeting
A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors.
First Author: Rita Nanda
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben